Benign Prostatic Hyperplasia Surgical Treatment Market Size Worth USD 3,412.57 Million by 2034 | CAGR: 5.3%

The benign prostatic hyperplasia surgical treatment market size is expected to reach USD 3,412.57 million by 2034, according to a new study by Polaris Market Research. The report “Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift], By End User, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/cultured-marble-market/request-for-sample

The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.

Top of FormBenign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights

• In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.
• Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.
• The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.
• Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.
• A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.

Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:

By Type Outlook (Revenue, USD Million, 2020–2034)

• Transurethral Resection of Prostate (TURP)
• Prostatic Urethral Lift
• Water Vapor Therapy
• Laser Therapy
• Aquablation Therapy
• Transurethral Microwave Thermotherapy (TUMT)
• Others

By End User Outlook (Revenue, USD Million, 2020–2034)

• Hospitals
• Ambulatory Surgery Centers and Clinics
• Homecare Settings

By Regional Outlook (Revenue, USD Million, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa